Company news
Metavia Inc. (NASDAQ:MTVA) news
Metavia Inc. news releases on 6ix. Latest, Sep 9, 2026: MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist…
Press releases & updates
MetaVia Announces Preclinical Findings Supporting Biological Rationale for DA-1726's Waist Circumference Reduction
September 9, 2026
MetaVia Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 6, 2026
MetaVia Announces Completion of Dose Titration in Phase 1 Part 3 Study of DA-1726 for the Treatment of Obesity
July 9, 2026
MetaVia Presents New Late-Breaking Obesity and Metabolic Data at the ADA 2026 Scientific Sessions Supporting DA-1726 Differentiation and Vanoglipel Combination Potential
June 8, 2026
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
May 27, 2026
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
May 20, 2026
MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
May 18, 2026
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 14, 2026
MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
May 11, 2026
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
April 9, 2026
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
March 25, 2026
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
March 17, 2026
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
March 11, 2026
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
March 4, 2026
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
February 17, 2026
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
February 13, 2026
MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel
February 4, 2026
MTVA: Positive Results for 48 mg Cohort in Phase 1b Trial of DA-1726…
January 21, 2026
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
January 16, 2026
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
January 15, 2026
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
January 5, 2026
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
December 29, 2025
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
December 22, 2025
MTVA: New Data for Vanoglipel (DA-1241) Presented at AASLD…
December 11, 2025
MetaVia Inc. Announces 1-for-11 Reverse Stock Split
December 2, 2025
MetaVia Presents Positive New Phase 2a Data on Vanoglipel (DA-1241) in Patients with Presumed MASH at the AASLD The Liver Meeting® 2025
November 7, 2025
MetaVia Reports Third Quarter 2025 Financial Results and Provides Corporate Update
November 6, 2025
MetaVia to Present New Phase 1 and Pre-Clinical Data on DA-1726 at ObesityWeek® 2025
November 4, 2025
MetaVia Announces Poster Presentation on Vanoglipel (DA-1241) at the AASLD Liver Meeting
October 27, 2025
MetaVia Announces Poster Presentations on DA-1726 at ObesityWeek® 2025
October 20, 2025
MetaVia to Present at the H.C. Wainwright Liver Disease Virtual Conference
October 14, 2025
MetaVia to Present at Upcoming Investor and Industry Conferences
August 26, 2025
MTVA: Results from 8-week Study of 48 mg DA-1726 Expected Before End of 2025…
August 13, 2025
MetaVia Reports Second Quarter 2025 Financial Results and Provides Corporate Update
August 7, 2025
MetaVia Extends 48 mg MAD Portion of Its Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity to 8 Weeks and Announces Fifth Weekly Dose in First Patient
August 6, 2025
MetaVia Announces AI-Driven Collaboration with Syntekabio to Explore Additional Indications for DA-1241
August 4, 2025
MetaVia Doses First Patient in the 48 mg MAD Cohort of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity to Further Explore Maximum Tolerated Dose
July 9, 2025
MTVA: DA-1241 in Combination with Efruxifermin Shows Additive Hepatoprotective Effects in Mouse MASH Model…
June 24, 2025
MetaVia Presents Pre-Clinical Data on DA-1241 Demonstrating Additive Hepatoprotective Effects in Combination With Efruxifermin at the ADA's 85th Scientific Session
June 21, 2025
MetaVia to Present at the Life Sciences Virtual Investor Forum June 12th
June 10, 2025
MetaVia Announces Poster Presentation on DA-1241 at the ADA's 85th Scientific Sessions
June 4, 2025
MTVA: Additional Positive Topline Results for DA-1726 in Phase 1 MAD Study…
May 22, 2025
MetaVia Reports First Quarter 2025 Financial Results and Provides Corporate Update
May 14, 2025
MetaVia Announces $10.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
May 9, 2025
MetaVia Presents Data on DA-1241, a GPR119 Agonist, Demonstrating Both Hepatoprotective and Glucose-Regulating Effects in Patients with Presumed MASH, at the EASL Congress 2025
May 7, 2025
MetaVia Announces Late-Breaking Poster Presentation on DA-1241 at the EASL Congress 2025
April 23, 2025
MetaVia Reports Additional Positive Top-Line Results From the MAD Part 2 of Its Phase 1 Study of DA-1726, a Novel 3:1 Ratio GLP-1 and Glucagon Dual Receptor Agonist to Treat Obesity, Further Demonstrating Its Best-In-Class Potential
April 22, 2025
MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Control (GLP-1R), Waist Reduction (GCGR), and Tolerability
April 15, 2025
MetaVia Announces Positive Top-Line Data From the 4-Week Phase 1 MAD Trial of DA-1726, a Novel 3:1 Ratio GLP-1 Glucagon Dual Receptor Agonist to Treat Obesity, Showing Compelling Weight Loss and Safety Effects With Potential Best-In-Class Glucose Cont...
April 14, 2025
MetaVia Reports Year End 2024 Financial Results and Provides Corporate Update
March 20, 2025